GSTM1 and ovarian cancer: reported similar results [21] showing that preoperative hematocrit <35 % (equivalent to a Hb of 11.7 g/dL) in patients with ovarian cancer undergoing CRS predicted poorer OS and DFS, especially in those with FIGO stage III and IV.